The Hoosier Cancer Research Network study HCRN GU14-188, a multicenter Phase Ib/II study of neoadjuvant pembrolizumab and cisplatin chemotherapy for muscle-invasive urothelial cancer, was featured as a podium session abstract May 5, 2019, during the American Urological Association (AUA) Annual Meeting in Chicago. The multi-center study is led by sponsor-investigator Christopher Hoimes, DO (pictured), of the Case Comprehensive Cancer Center at University Hospitals-Seidman Cancer Center. The abstract was presented by Hristos Kaimakliotis, MD, of the Indiana University School of Medicine.

Abstract Title: PD52-03: A multicenter Phase Ib/II study of neoadjuvant pembrolizumab and cisplatin chemotherapy for muscle-invasive urothelial cancer

Authors: Hristos Kaimakliotis, Costantine Albany, Jean Hoffman-Censits, Edouard Trabulsi, W. Kevin Kelly, Joel Picus, Nabil Adra, Clint Cary, Michael Koch, Mark Fleming, Radhika Walling, J. Luke Godwin, Robert Abouassaly, Matthew Cooney, Pingfu Fu, Ariel Nelson, Ginu Xavier, Lee Ponsky, and Christopher Hoimes.

See full abstract.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 210 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 8,500 subjects have participated in Hoosier Cancer Research Network clinical trials.